FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318382649> ?p ?o ?g. }

• W2318382649 endingPage "585" @default.
• W2318382649 startingPage "577" @default.
• W2318382649 abstract "BACKGROUND: Oxaliplatin is used in adjuvant treatment of colorectal cancer and is associated with sinusoidal obstruction syndrome. Few data are available on its effects in patients in whom portal hypertension was diagnosed before cancer treatment. OBJECTIVE: Our aim was to investigate short- and long-term outcomes of surgery for colorectal cancer in patients with portal hypertension with or without cirrhosis, particularly regarding effects of adjuvant chemotherapy with oxaliplatin. DESIGN AND SETTING: This was a prospective cohort study performed at an academic medical center. PATIENTS: Patients with stage II or III colorectal cancer and portal hypertension who underwent curative resection were included. INTERVENTION: All patients received adjuvant chemotherapy with oxaliplatin (FOLFOX 4) or 5-fluorouracil and leucovorin. MAIN OUTCOME MEASURES: Potential predictive laboratory and clinical variables and postoperative (30-day) and long-term morbidity and mortality were recorded. RESULTS: Of 63 patients enrolled, 23 (37%) had a total of 82 postoperative complications; 5 patients (8%) died within 30 days postoperatively. Univariate analysis showed that severe portal hypertension, preoperative Child class B, low albumin, the presence of ascites, preoperative upper GI tract bleeding, and high intraoperative blood loss were linked to postoperative morbidity. Presence of postoperative infection (p = 0.004), presence of preoperative ascites (p = 0.01), high intraoperative blood loss (p = 0.02), and preoperative upper GI tract bleeding (p = 0.03) were significantly related to mortality. Of 58 patients receiving adjuvant chemotherapy, 20 received the oxaliplatin regimen and 38 received 5-fluorouracil/leucovorin without oxaliplatin. The median length of follow-up was 26 (range, 6–36) months. Kaplan-Meier analyses showed that patients who received oxaliplatin had higher cumulative incidences of newly developed esophageal varices (p = 0.002), GI tract bleeding (p = 0.02), and newly formed ascites (p = 0.03). Death occurred in 8 of 20 patients (40%) in the oxaliplatin group and in 5 of 38 patients (13%) in the 5-fluorouracil group. Kaplan-Meier estimates of mean survival time were 34.4 months (95% CI, 32.4–36.5) in the 5-fluorouracil/leucovorin group vs 29.9 months (95% CI, 26–33.7) in the oxaliplatin group, and patients receiving oxaliplatin had a significantly higher relative risk of death (HR = 2.98; 95% CI, 1.03–8.65). Cancer-specific mortality was not related to treatment type. LIMITATIONS: The study was limited by the relatively small sample size and lack of randomization, which may have led to selection bias in treatment regimens. CONCLUSIONS: Colorectal cancer surgery can be done safely in portal hypertensive patients with good hepatic function; however, higher mortality is expected in patients with compromised hepatic function reserve. Compared with adjuvant chemotherapy without oxaliplatin, oxaliplatin-based chemotherapy does not significantly reduce cancer-specific mortality and may increase overall morbidity and mortality. Therefore, oxaliplatin-based chemotherapy should be used with caution in patients who have portal hypertension, even in those with good liver function." @default.
• W2318382649 created "2016-06-24" @default.
• W2318382649 creator A5027818200 @default.
• W2318382649 creator A5044599926 @default.
• W2318382649 creator A5064588416 @default.
• W2318382649 date "2013-05-01" @default.
• W2318382649 modified "2023-10-16" @default.
• W2318382649 title "Colorectal Cancer Surgery in Portal Hypertensive Patients" @default.
• W2318382649 cites W1607874499 @default.
• W2318382649 cites W1975347594 @default.
• W2318382649 cites W1979940541 @default.
• W2318382649 cites W1995617921 @default.
• W2318382649 cites W2025410458 @default.
• W2318382649 cites W2042044059 @default.
• W2318382649 cites W2052216750 @default.
• W2318382649 cites W2060123467 @default.
• W2318382649 cites W2111484764 @default.
• W2318382649 cites W2131745440 @default.
• W2318382649 cites W2134845794 @default.
• W2318382649 cites W2138170697 @default.
• W2318382649 cites W2143007780 @default.
• W2318382649 cites W2145683577 @default.
• W2318382649 cites W2145984675 @default.
• W2318382649 cites W2147279337 @default.
• W2318382649 cites W2154230241 @default.
• W2318382649 cites W2163123611 @default.
• W2318382649 cites W2171232394 @default.
• W2318382649 cites W4206022937 @default.
• W2318382649 doi "https://doi.org/10.1097/dcr.0b013e318286f8fc" @default.
• W2318382649 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23575396" @default.
• W2318382649 hasPublicationYear "2013" @default.
• W2318382649 type Work @default.
• W2318382649 sameAs 2318382649 @default.
• W2318382649 citedByCount "7" @default.
• W2318382649 countsByYear W23183826492015 @default.
• W2318382649 countsByYear W23183826492016 @default.
• W2318382649 countsByYear W23183826492017 @default.
• W2318382649 countsByYear W23183826492021 @default.
• W2318382649 countsByYear W23183826492023 @default.
• W2318382649 crossrefType "journal-article" @default.
• W2318382649 hasAuthorship W2318382649A5027818200 @default.
• W2318382649 hasAuthorship W2318382649A5044599926 @default.
• W2318382649 hasAuthorship W2318382649A5064588416 @default.
• W2318382649 hasConcept C121608353 @default.
• W2318382649 hasConcept C126322002 @default.
• W2318382649 hasConcept C141071460 @default.
• W2318382649 hasConcept C2777214474 @default.
• W2318382649 hasConcept C2778260052 @default.
• W2318382649 hasConcept C2778808290 @default.
• W2318382649 hasConcept C2780962732 @default.
• W2318382649 hasConcept C2781413609 @default.
• W2318382649 hasConcept C526805850 @default.
• W2318382649 hasConcept C71924100 @default.
• W2318382649 hasConcept C90924648 @default.
• W2318382649 hasConceptScore W2318382649C121608353 @default.
• W2318382649 hasConceptScore W2318382649C126322002 @default.
• W2318382649 hasConceptScore W2318382649C141071460 @default.
• W2318382649 hasConceptScore W2318382649C2777214474 @default.
• W2318382649 hasConceptScore W2318382649C2778260052 @default.
• W2318382649 hasConceptScore W2318382649C2778808290 @default.
• W2318382649 hasConceptScore W2318382649C2780962732 @default.
• W2318382649 hasConceptScore W2318382649C2781413609 @default.
• W2318382649 hasConceptScore W2318382649C526805850 @default.
• W2318382649 hasConceptScore W2318382649C71924100 @default.
• W2318382649 hasConceptScore W2318382649C90924648 @default.
• W2318382649 hasIssue "5" @default.
• W2318382649 hasLocation W23183826491 @default.
• W2318382649 hasLocation W23183826492 @default.
• W2318382649 hasOpenAccess W2318382649 @default.
• W2318382649 hasPrimaryLocation W23183826491 @default.
• W2318382649 hasRelatedWork W1978017914 @default.
• W2318382649 hasRelatedWork W2037039278 @default.
• W2318382649 hasRelatedWork W2136984368 @default.
• W2318382649 hasRelatedWork W2138294834 @default.
• W2318382649 hasRelatedWork W2235788479 @default.
• W2318382649 hasRelatedWork W2297296679 @default.
• W2318382649 hasRelatedWork W2569965908 @default.
• W2318382649 hasRelatedWork W2809146871 @default.
• W2318382649 hasRelatedWork W3110357236 @default.
• W2318382649 hasRelatedWork W3140349894 @default.
• W2318382649 hasVolume "56" @default.
• W2318382649 isParatext "false" @default.
• W2318382649 isRetracted "false" @default.
• W2318382649 magId "2318382649" @default.
• W2318382649 workType "article" @default.